Medicure Completes Enrollment in Pivotal Phase 3 Trial for Ultra-Rare PNPO Deficiency
MCUJF has more than doubled off its 52-week low of $0.436 on elevated volume (1.9× avg).
Summary
Medicure has completed enrollment in its MEND-PNPO Phase 3 trial, reaching the target of 10 patients for MC-1 in PNPO deficiency. This is a key milestone for an ultra-rare disease program with no approved therapy. The company holds FDA Rare Pediatric Disease, Orphan Drug, and Fast Track designations, and is eligible for a Priority Review Voucher upon NDA approval. With enrollment complete, focus shifts to patient follow-up and potential NDA submission. The stock is trading near its 52-week high, reflecting heightened investor attention on this catalyst.
At the time of this announcement, MCUJF was trading at $2.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $20.9M. The 52-week trading range was $0.44 to $2.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.